AstraZeneca (LON:AZN) had its price target boosted by Goldman Sachs Group from GBX 4,080 ($53.31) to GBX 5,000 ($65.33) in a research report sent to investors on Tuesday. They currently have a sell rating on the biopharmaceutical company’s stock.

AZN has been the topic of several other research reports. Barclays reissued an overweight rating on shares of AstraZeneca in a research report on Monday, January 21st. JPMorgan Chase & Co. reissued a buy rating on shares of AstraZeneca in a research report on Tuesday, January 22nd. Societe Generale boosted their target price on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the stock a buy rating in a research report on Wednesday, January 16th. Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a report on Monday, February 25th. Finally, Deutsche Bank reaffirmed a buy rating and issued a GBX 6,900 ($90.16) price objective on shares of AstraZeneca in a report on Monday, February 18th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. AstraZeneca presently has a consensus rating of Buy and a consensus target price of GBX 6,282.20 ($82.09).

LON:AZN opened at GBX 6,312 ($82.48) on Tuesday. AstraZeneca has a twelve month low of GBX 4,260 ($55.66) and a twelve month high of GBX 5,520 ($72.13).

The company also recently announced a dividend, which will be paid on Wednesday, March 27th. Investors of record on Thursday, February 28th will be paid a GBX 146.80 ($1.92) dividend. This is a boost from AstraZeneca’s previous dividend of $68.40. This represents a dividend yield of 2.57%. The ex-dividend date is Thursday, February 28th.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Further Reading: How Does the Quiet Period Work?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.